FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...
Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...
New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...
Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...
The pivotal MajesTEC-3 trial led to FDA approval of teclistamab-daratumumab for relapsed/refractory multiple myeloma after at ...
Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines ...
During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.
NCCN now recognizes image-only, mammogram-derived AI as a primary risk tool, shifting risk stratification from ...
The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results